FBRX vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FBRX Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Forte Biosciences, Inc. Common Stock (FBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, FBRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, FBRX sits in UNCLASSIFIED (3rd %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FBRX Revenue | LCTX Revenue | FBRX Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $20M | $0M | -254.2% | -837.9% | FBRX |
| FY2019 | $0M | $0M | -11288.9% | -1106.0% | LCTX |
| FY2020 | N/A | $0M | N/A | -1448.4% | LCTX |
| FY2021 | N/A | $0M | N/A | -1133.6% | LCTX |
| FY2022 | N/A | $10M | N/A | -153.2% | LCTX |
| FY2023 | N/A | $10M | N/A | -276.5% | LCTX |
| FY2024 | N/A | $10M | N/A | -226.1% | LCTX |
| FY2025 | N/A | $10M | N/A | -251.6% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FBRX | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.6B | $207.4M | Larger Scale | FBRX |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +0.0% | -61.0% | Higher Growth | FBRX |
| Operating Margin (TTM) Profitability | 0.0% | -280.3% | Higher Margin | FBRX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -62.3% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 100% ($10โ$77) | 0% ($1โ$2) | Stronger Trend | FBRX |
| Beta / 30D Volatility Risk Regime | 1.09ฮฒ ยท 3% Vol | 1.39ฮฒ ยท 79% Vol | Lower Realized Risk | FBRX |
| Unified Institutional Score Composite Signal | 52.7 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | LCTX |